Kidney disorder therapeutics - Teijin Pharma
Latest Information Update: 25 Apr 2023
At a glance
- Originator Teijin Pharma
- Developer Novartis; Teijin Pharma
- Class Small molecules; Urologics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Proteinuria